How to buy Takeda Pharmaceutical (TAK) shares in Australia
Learn how to easily invest in Takeda Pharmaceutical shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Takeda Pharmaceutical Co Ltd ADR is a drug manufacturers-specialty & generic business with stocks listed in the US. Takeda Pharmaceutical shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$13.86 – an increase of 1.54% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Takeda Pharmaceutical
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Takeda Pharmaceutical. Find the share by name or ticker symbol: TAK. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Takeda Pharmaceutical reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$13.86, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Takeda Pharmaceutical, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Takeda Pharmaceutical. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Takeda Pharmaceutical key stats
- Compare share trading platforms
- Is Takeda Pharmaceutical stock a buy or sell?
- Takeda Pharmaceutical performance over time
- Are Takeda Pharmaceutical shares over-valued?
- Takeda Pharmaceutical's financials
- How volatile are Takeda Pharmaceutical shares?
- Does Takeda Pharmaceutical pay a dividend?
- Other common questions
Takeda Pharmaceutical stock price (NYSE:TAK)Use our graph to track the performance of TAK stocks over time.
Takeda Pharmaceutical shares at a glance
|52-week range||US$13.05 - US$17.31|
|50-day moving average||US$14.2224|
|200-day moving average||US$14.5394|
|Dividend yield||US$180 (5.81%)|
|Earnings per share (TTM)||US$0.54|
Compare trading apps to buy Takeda Pharmaceutical shares
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Takeda Pharmaceutical stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Takeda Pharmaceutical price performance over time
|1 week (2022-06-22)||1.54%|
|1 month (2022-05-27)||-6.16%|
|3 months (2022-03-30)||-3.95%|
|6 months (2021-12-30)||2.06%|
|1 year (2021-06-30)||-17.65%|
|2 years (2020-06-30)||-22.70%|
|3 years (2019-06-28)||-21.69%|
|5 years (2017-06-29)||-45.69%|
Stocks similar to Takeda Pharmaceutical
Is Takeda Pharmaceutical under- or over-valued?
Valuing Takeda Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Takeda Pharmaceutical's P/E ratio
Takeda Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Takeda Pharmaceutical shares trade at around 26x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Takeda Pharmaceutical's PEG ratio
Takeda Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4767. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Takeda Pharmaceutical's EBITDA
Takeda Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$1,452 billion (£1,197 billion).
The EBITDA is a measure of a Takeda Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
Takeda Pharmaceutical financials
|Revenue TTM||US$3,569 billion|
|Operating margin TTM||24.34%|
|Gross profit TTM||US$2,462.2 billion|
|Return on assets TTM||4.16%|
|Return on equity TTM||4.24%|
|Market capitalisation||US$43 billion|
TTM: trailing 12 months
Takeda Pharmaceutical share dividends
Dividend payout ratio: 56.75% of net profits
Recently Takeda Pharmaceutical has paid out, on average, around 56.75% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.81% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical shareholders could enjoy a 5.81% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical's case, that would currently equate to about $180 per share.
Takeda Pharmaceutical's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Takeda Pharmaceutical's most recent dividend payout was on 15 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2021 (the "ex-dividend date").
Takeda Pharmaceutical share price volatility
Over the last 12 months, Takeda Pharmaceutical's shares have ranged in value from as little as US$13.05 up to US$17.31. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical's is 0.8993. This would suggest that Takeda Pharmaceutical's shares are less volatile than average (for this exchange).
Takeda Pharmaceutical overview
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Takeda Pharmaceutical in the news
Takeda Is ‘Now In a Good Phase’ for Growth, CEO Weber Says
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Takeda leases future Kendall Square building
Frequently asked questions
More guides on Finder
How to buy Kincora Copper (KCC) shares
Steps to owning and managing Kincora Copper shares.
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
How to buy 5E Advanced Materials (5EA) shares
Steps to owning and managing 5E Advanced Materials shares.
How to buy Leo lithium shares
Steps to owning and managing Leo lithium shares.
How to buy Besra Gold (BEZ) shares
Steps to owning and managing Besra Gold shares.
Ask an Expert